Shijiazhuang Yiling Pharmaceutical (002603.SZ) expects to incur a net loss of 600 million to 800 million in 2024, turning from profit to loss compared to the previous year.

Shijiazhuang Yiling Pharmaceutical (002603.SZ) released its 2024 annual performance forecast, predicting a net loss of 600 million to 800 million yuan attributable to shareholders of the listed company for the full year, a change from profit to loss compared to the previous year. During the reporting period, some respiratory system products are nearing expiration, and the company plans to reduce related product sales revenue and make provision for impairment losses on inventory nearing expiration. In addition, the decrease in revenue, the rise in raw material prices leading to a decrease in gross profit margin, and continued high research and development investment have all contributed to a substantial decrease in operating profit for the year 2024, resulting in a loss.